In hepatocellular carcinoma, FASN blockade was found to increase MHC-I antigen presentation on tumor cells, enhancing their recognition by CD8+ T cells and synergizing with PD-1/PD-L1 blockade (84). Here, CD8A is linked to neoplasm.